Long-term amelioration of telmisartan on metabolic syndrome-related molecules in stroke-resistant spontaneously hypertensive rat after transient middle cerebral artery occlusion

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2646-2653. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.012. Epub 2014 Oct 11.

Abstract

Telmisartan is expected to ameliorate not only hypertension, but also metabolic syndrome as a metabosartan. We examined the effects of telmisartan on metabolic syndrome-related molecules such as insulin receptor (IR), peroxisome proliferator-activated receptor gamma (PPAR-γ), and angiotensin 2 type 1 receptor (AT1R) in stroke-resistant spontaneously hypertensive rat (SHR-SR) after transient middle cerebral artery occlusion (tMCAO), by administering telmisartan at either 0 (vehicle), .3 mg/kg/day (low dose), or 3 mg/kg/day (high dose), postoperatively, from 3 months of age and performed immunohistologic analysis at 6, 12, and 18 months of age. Compared with the vehicle group, the 2 telmisartan groups dose dependently decreased the number of IR- and AT1R-positive neurons in the cerebral cortex in the ipsilateral cerebral cortex from 6 to 18 months after tMCAO. On the other hand, the number of PPAR-γ-positive neurons increased in a dose-dependent manner in the 2 telmisartan groups from 6 to 18 months. The present study suggests that telmisartan dose-dependently ameliorated metabolic syndrome-related changes in the poststroke brain of SHR-SR with a direct protective effect (low dose) and an additive benefit, an antihypertensive effect at a high dose, for long-term protection after tMCAO.

Keywords: Angiotensin 2 type 1 receptor; ischemic stroke; metabolic syndrome; peroxisome proliferator-activated receptor gamma; spontaneously hypertensive rat; transient middle cerebral artery occlusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / pharmacology*
  • Benzoates / administration & dosage
  • Benzoates / pharmacology*
  • Cerebral Cortex / cytology
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Infarction, Middle Cerebral Artery / complications
  • Male
  • Metabolic Syndrome / drug therapy
  • Metabolic Syndrome / metabolism*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology
  • PPAR gamma / metabolism
  • Rats
  • Rats, Inbred SHR
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Insulin / metabolism
  • Stroke / drug therapy*
  • Stroke / metabolism*
  • Telmisartan
  • Time Factors
  • Treatment Outcome

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Benzoates
  • Neuroprotective Agents
  • PPAR gamma
  • Receptor, Angiotensin, Type 1
  • Receptor, Insulin
  • Telmisartan